Antibiotic Resistance News and Research

RSS

NanoLogix BNP and BNF Quick Test kits detect, identify Group B Strep in four to six hours

NanoLogix, a biotechnology innovator in the rapid detection and identification of live-cell bacteria and microorganisms, announced today that the American Journal of Perinatology has published a peer-reviewed paper from the University of Texas Health Science Center - Houston confirming NanoLogix BioNanoPore (BNP) and BioNanoFilter (BNF) Quick Test technology detect and identify Group B Strep in four to six hours.

8 Aug 2011

SMRT DNA sequencing technology reveals genetic profile of German E. coli bacteria

An international team of scientists has successfully employed single molecule, real-time DNA sequencing technology from Pacific Biosciences of California, Inc. to provide valuable insights into the pathogenicity and evolutionary origins of the highly virulent bacterium responsible for the German E. coli outbreak.

28 Jul 2011

New rapid test accurately distinguishes bacterial and viral infections

Researchers at Ben-Gurion University of the Negev (BGU) have developed a new test that quickly and accurately distinguishes between bacterial and viral infections in as little as five hours.

21 Jul 2011

EU countries should pool funding to create 'prize' for bringing new antibiotics to market, report says

"European policy makers were urged Wednesday to find viable financial incentives to get drug companies to discover new antibiotics, because the lack of fresh supplies poses acute dangers to health care and efforts against infectious diseases," according to a report by the Office of Health Economics and funded by GlaxoSmithKline, Dow Jones/Wall Street Journal reports.

8 Jul 2011

Scientists track public health trends through Twitter

Twitter allows millions of social media fans to comment in 140 characters or less on just about anything: an actor's outlandish behavior, an earthquake's tragic toll or the great taste of a grilled cheese sandwich.

8 Jul 2011

Antibiotic resistance is not a priority in the U.S.

Author and journalist Maryn McKenna in her "Superbug" blog on Wired.com examines U.S. spending on drug-resistant pathogens, including methicillin-resistant Staphylococcus aureus.

7 Jul 2011

Antimicrobial copper surfaces reduce risk of acquiring hospital infection

Professor Bill Keevil, Head of the Microbiology Group and Director of the Environmental Healthcare Unit at the University of Southampton, has presented research into the mechanism by which copper exerts its antimicrobial effect on antibiotic-resistant organisms at the World Health Organization's first International Conference on Prevention and Infection Control.

2 Jul 2011

Bdellovibrio safe and effective for treating Salmonella infection

Scientists have tested a predatory bacterium - Bdellovibrio - against Salmonella in the guts of live chickens. They found that it significantly reduced the numbers of Salmonella bacteria and, importantly, showed that Bdellovibrio are safe when ingested.

28 Jun 2011

Low-level antibiotic exposure may cause E. coli bacteria to develop resistance

E. coli bacteria exposed to three common antibiotics were more likely to develop antibiotic resistance following low-level antibiotic exposure than after exposure to high concentrations that would kill the bacteria or inhibit their growth, according to a timely article in Microbial Drug Resistance, a peer-reviewed journal published by Mary Ann Liebert, Inc.

15 Jun 2011

GlycoVaxyn's Second Annual Science Day to highlight challenges of vaccine industry

GlycoVaxyn AG, a leader in the development of conjugate vaccines, today announced that it will host its Second Annual Science Day to discuss challenges and opportunities in vaccine development on June 16-17, 2011, in Cannes, France.

15 Jun 2011

NIH awards $1.9M grant to Scripps Research scientist for malaria study

A scientist from The Scripps Research Institute has won a four-year, $1.9 million grant from the National Institutes of Health to better understand the parasite that causes malaria, laying the groundwork to develop better drugs to combat the widespread and deadly disease.

10 Jun 2011

University of Perugia researcher to lead BioNanoFilter European clinical trial on Group B Strep

NanoLogix, a biotechnology innovator in the rapid detection and identification of live-cell bacteria and microorganisms, announced today its BioNanoFilter (BNF) technology will undergo a clinical trial, led by Dr. Gian Carlo Di Renzo of the University of Perugia in Italy.

7 Jun 2011

BGI genome sequencing identifies new super-toxic bacteria as cause of current European epidemic

The recent outbreak of an E. coli infection in Germany has resulted in serious concerns about the potential appearance of a new deadly strain of bacteria.

4 Jun 2011

Mimicry allows bacteria to evade host's defense responses

Deadly bacteria may be evolving antibiotic resistance by mimicking human proteins, according to a new study by the Translational Genomics Research Institute (TGen).

3 Jun 2011

E coli outbreak in Germany continues

As the current virulent Shiga toxin-producing Escherichia coli (STEC) outbreak in Germany spreads, experts from The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) are concerned not only about the pressure health facilities are being put under, but also the use of antibiotics and broader implications for preparedness across Europe to cope, both now and in the future.

3 Jun 2011

CMAJ report outlines challenges, approaches to manage and identify NDM-1 antibiotic resistant enzyme

An enzyme associated with extensive antibiotic resistance called New Delhi metallo---lactamase-1 (NDM-1), endemic in India and Pakistan and spreading worldwide, has been found in two people in the Toronto area, one of whom acquired it in Canada, states a case report in CMAJ.

31 May 2011

Australians discover treatment for very common female infection

Starpharma Holdings Limited has announced successful results of a major phase 2 clinical study that demonstrated efficacy of VivaGel® for the treatment of bacterial vaginosis (BV).

22 May 2011

Mpex, Synteract partner for cystic fibrosis fundraising event

Synteract, Inc., a full-service, global contract research organization, and Mpex Pharmaceuticals, a biopharmaceutical company developing new therapies to combat the growing issue of antibiotic resistance, have partnered for the second annual Great Strides fundraiser to benefit cystic fibrosis.

19 May 2011

Tips for fighting drug-resistant superbugs

Superbug CRKP is just the latest in emerging strains of drug-resistant bacteria. While new drugs to combat these stealthy microbes like MRSA and CRKP remain in development what can we do to prevent catching and spreading these dangerous bugs?.

13 May 2011

Tetraphase presents TP-434, TP-2758 antibiotics study data against pathogens at ECCMID

Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on next-generation antibiotics, announced today that it is presenting new results of several studies designed to support the continued advancement of its lead antibiotic, TP-434, a potent new broad-spectrum intravenous antibiotic with oral stepdown potential effective against difficult-to-treat and multidrug-resistant pathogens.

10 May 2011